Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: A possible model of Alzheimer's disease

Neurobiology of Learning and Memory

Volumn 68, Issue 3, 1997, Pages 333-342

  Bartolomeo, Adam C ^a   Morris, Herman ^a   Boast, Carl A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARECOLINE; ETHYLCHOLINE MUSTARD AZIRIDINIUM;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; MALE; MAZE TEST; NONHUMAN; OSMOTIC PUMP; PERFORMANCE; RAT; STEREOTAXIS;

EID: 0031281323     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1006/nlme.1997.3786     Document Type: Article

References (28)

1. Asthana S., Greig N. H., Holloway H. W., Raffaele K. C., Berardi A., Schapiro M. B., Rapoport S. I., Soncrant T. T. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Clinical Pharmacology and Therapeutics. 60:1996;276-282.
2. Bratt A. M., Kelly M. E., Domeney A. M., Naylor R. J., Costall B. Acute and chronic arecoline: Effects on a scopolamine-induced deficit in complex maze learning. Pharmacology, Biochemistry and Behavior. 53:1996;713-721.
3. Chrobak J. J., Hanin I., Schmechel D. E., Walsh T. J. AF64A-induced working memory impairment: Behavioral, neurochemical and histological correlates. Brain Research. 463:1988;107-117.
4. Chrobak J. J., Spates M. J., Stackman R. W., Walsh T. J. Hemicholinium-3 prevents the working memory impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A). Brain Research. 504:1989;269-275.
5. el-Tamer A., Corey J., Wulfert E., Hanin I. Reversible cholinergic changes induced by AF64A in rat hippocampus and possible septal compensatory effects. Neuropharmacology. 31:1992;397-402.
6. 1. Neuroscience Letters. 102:1989;325-331.
7. Fisher A., Heldman E., Gurwitz D., Haring R., Karton Y., Meshulam H., Pittel Z, . Marciano D., Brandeis R., Sadot E., Barg Y., Pinkas-Kramarski R., Vogel Z., Ginzburg I., Treves T. A., Verchovsky R., Klimowsky S., Korczyn A. D. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Annals of the New York Academy of Sciences. 777:1996;189-196.
8. Hanin I., Fisher A., Hortnagl H., Leventer S. M., Potter P. E., Walsh T. J. Ethylcholine aziridinium (AF64A; ECMA) and other potential cholinergic neuron-specific neurotoxins. Psychopharmacology: The third generation of progress. 1987;Raven Press, New York. p. 341-349.
9. Jope R. S., Song L., Li X., Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiology of Aging. 15:1994;221-226.
10. Ladner C. J., Celesia G. G., Magnuson D. J., Lee J. M. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology. 54:1995;783-789.
11. Leventer S. M., McKeag D., Clancy M., Wulfert E., Hanin I. Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices. Neuropharmacology. 24:1985;453-459.
12. Leventer S. M., Wulfert E., Hanin I. Time course of ethylcholine aziridinium ion (AF64A)-induced cholinotoxicity in vitro. Neuropharmacology. 26:1987;361-365.
13. Locasio J. J., Growdon J. H., Corkin S. Cognitive test performance in detecting, staging and tracking Alzheimer's disease. Archives of Neurology. 52:1995;1087-1099.
14. Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
15. Luine V., Hearns M. Spatial memory deficits in aged rats: Contributions of the cholinergic system assessed by ChAT. Brain Research. 523:1990;321-324.
16. Maneesub Y., Sanvarinda Y., Govitrapong P. Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E. Neurochemistry International. 22:1993;487-491.
17. McKinney M., Coyle J. T. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clinic Proceedings. 66:1991;1225-1237.
18. Miyamoto M., Narumi S., Nagaoka A., Coyle J. T. Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. Journal of Pharmacology and Experimental Therapeutics. 248:1989;825-835.
19. Morris H., Maurer S. A., Storch F. E., Boast C. A. Chronic infusion of muscarinic agonists may be necessary to attenuate AF64A cognitive impairments in rats. Society for Neuroscience Abstracts. 18:1992;518.
20. Nakahara N., Iga Y., Saito Y., Mizobe F., Kawanishi G. Beneficial effects of FKS-508 (AF102B), a selective M1 agonist, on the impaired working memory in AF64A-treated rats. Japanese Journal of Pharmacology. 51:1989;539-547.
21. Olton D. S. The use of animal models to evaluate the effects of neurotoxins on cognitive processes. Neurobehavioral Toxicology and Teratology. 5:1983;635-640.
22. Quirion R., Aubert I., Lapchak P. A., Schaum R. P., Teolis S., Gauthier S., Araujo D. M. Muscarinic receptor subtypes in human neurodegenerative disorders: Focus on Alzheimer's disease. Trends in Pharmaceutical Sciences Supplement. December:1989;80-84.
23. Ricci A., Mancini M., Strocchi P., Bongrani S., Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: Sensitivity to treatment with the monoamine oxidase-B inhibitor 1-deprenyl. Drugs Under Experimental Clinical Research. 18:1992;163-171.
24. Soncrant T. T., Raffaele K. C., Asthana S., Berardi A., Morris P. P., Haxby J. V. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology. 112:1993;421-427.
25. Stewart D. J., Leventer S. M., Hanin I., Vanderwolf C. H. Hippocampal electrical activity in relation to behavior following ethylcholine aziridinium ion (AF64A) treatment. Pharmacology, Biochemistry and Behavior. 26:1987;357-364.
26. Walsh T. J., Tilson H. A., DeHaven D. L., Mailman R. B., Fisher A., Hanin I. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat. Brain Research. 321:1984;91-102.
27. Wenk G., Sweeney J., Hughey D., Carson J., Olton D. Cholinergic function and memory: Extensive inhibition of choline acetyltransferase fails to impair radial maze performance in rats. Pharmacology Biochemistry and Behavior. 25:1986;521-526.
28. Xiong Z. Q., Han Y. F., Tang X. C. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuro Report. 6:1995;2221-2224.